Seqens, a developer and producer of active pharmaceutical ingredients, pharmaceutical intermediates, and specialty ingredients, has named Pascal Villemagne as Chief Executive Officer, effective April ...

TekniPlex, an advanced materials science company, has named long-tenured senior executive Suj Mehta as CEO of its Healthcare ...

Arcus Biosciences, Inc. has regained ownership of casdatifan, a potential treatment for clear cell renal cell carcinoma (ccRCC), after Gilead’s time-limited exclusive option rights to casdatifan ...

The U.S. Food and Drug Administration (FDA) has approved for review a Biologics License Application (BLA) for AVT06, Alvotech ...

Asahi Kasei Bioprocess America Inc. (AKBA), a leader in advanced filtration and fluid management solutions for the ...

Flourish Research, a multi-site clinical trial organization focused primarily on cardiovascular, metabolic, neuroscience, and ...

The US Food and Drug Administration (FDA) has accepted for priority review Sanofi’s supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid ...

The success of NIPRO’s biosimilar product, launched in late 2023, has exceeded expectations and gained significant market ...

This eBook is your guide for navigating partnerships with Contract Manufacturing Organizations (CMOs) in the pharma and biopharma world.

Sanofi and Johnson & Johnson’s E. coli vaccine candidate failed to prevent invasive E. coli disease effectively.

Glenmark Pharmaceuticals Inc. USA has launched Latanoprost Ophthalmic Solution, a 0.005% (0.05 mg/mL) ophthalmic solution. This product is bioequivalent and therapeutically equivalent to the reference ...